KR102345381B1 - 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 - Google Patents

키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 Download PDF

Info

Publication number
KR102345381B1
KR102345381B1 KR1020167001634A KR20167001634A KR102345381B1 KR 102345381 B1 KR102345381 B1 KR 102345381B1 KR 1020167001634 A KR1020167001634 A KR 1020167001634A KR 20167001634 A KR20167001634 A KR 20167001634A KR 102345381 B1 KR102345381 B1 KR 102345381B1
Authority
KR
South Korea
Prior art keywords
carbazole
methylphenyl
carboxamide
dioxo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167001634A
Other languages
English (en)
Korean (ko)
Other versions
KR20160022890A (ko
Inventor
수 성 고
더글러스 쥐. 배트
마이라 보두인 버트런드
조지 브이. 델루카
찰스 엠. 랜저빈
칭제 류
아누라그 에스. 스리바스타바
스콧 헌터 와터슨
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20160022890A publication Critical patent/KR20160022890A/ko
Application granted granted Critical
Publication of KR102345381B1 publication Critical patent/KR102345381B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020167001634A 2013-06-25 2014-06-25 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 Expired - Fee Related KR102345381B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361839130P 2013-06-25 2013-06-25
US61/839,130 2013-06-25
PCT/US2014/043980 WO2014210087A1 (en) 2013-06-25 2014-06-25 Carbazole carboxamide compounds useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20160022890A KR20160022890A (ko) 2016-03-02
KR102345381B1 true KR102345381B1 (ko) 2021-12-29

Family

ID=51210832

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167001634A Expired - Fee Related KR102345381B1 (ko) 2013-06-25 2014-06-25 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물

Country Status (13)

Country Link
US (1) US9714234B2 (OSRAM)
EP (1) EP3013815B1 (OSRAM)
JP (1) JP6353530B2 (OSRAM)
KR (1) KR102345381B1 (OSRAM)
CN (1) CN105473573B (OSRAM)
AU (1) AU2014302550A1 (OSRAM)
BR (1) BR112015031432A2 (OSRAM)
CA (1) CA2916504A1 (OSRAM)
EA (1) EA025863B1 (OSRAM)
IL (1) IL243295A0 (OSRAM)
MX (1) MX2015016771A (OSRAM)
SG (1) SG11201510028PA (OSRAM)
WO (1) WO2014210087A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511209B (zh) 2014-10-24 2022-07-05 百时美施贵宝公司 可用作激酶抑制剂的吲哚甲酰胺化合物
SG10201903621SA (en) 2014-10-24 2019-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds
HRP20192197T2 (hr) 2014-10-24 2020-11-13 Bristol-Myers Squibb Company Derivati karbazola
CN105802100A (zh) * 2016-04-22 2016-07-27 宁波硫华聚合物有限公司 橡胶促进剂粘合剂六甲氧基甲基蜜胺预分散母胶粒及其制备方法
CN105670057A (zh) * 2016-04-25 2016-06-15 无锡智谷锐拓技术服务有限公司 一种耐油橡胶的制备方法
CN105694150A (zh) * 2016-04-25 2016-06-22 无锡智谷锐拓技术服务有限公司 一种耐油橡胶
CN106084903A (zh) * 2016-06-02 2016-11-09 扬州兰都塑料科技有限公司 一种电缆外部涂覆的水性防火涂料的制备方法
CN105907150A (zh) * 2016-06-02 2016-08-31 扬州兰都塑料科技有限公司 一种电缆涂料用阻燃剂
CN106045972B (zh) * 2016-06-03 2018-11-16 中山大学 咔唑-利凡斯的明二联体及其药物组合物和应用
CN115335380B (zh) 2020-02-03 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的三环杂芳基化合物
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
EP1831227B1 (en) 2004-12-17 2013-06-19 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP1954290B1 (en) 2005-11-22 2012-07-25 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
CA2663178C (en) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
AU2008335761B2 (en) 2007-12-13 2014-04-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8318132B2 (en) 2008-02-14 2012-11-27 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2307418B1 (en) * 2008-07-18 2014-03-12 F.Hoffmann-La Roche Ag Novel phenylimidazopyrazines
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
SG171815A1 (en) * 2008-12-19 2011-07-28 Bristol Myers Squibb Co Carbazole carboxamide compounds useful as kinase inhibitors
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
BR112013029620A2 (pt) 2011-05-17 2016-09-06 Hoffmann La Roche inibidores de tirosina quinase de bruton
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
EA025863B1 (ru) 2017-02-28
EA201690012A1 (ru) 2016-05-31
CN105473573B (zh) 2018-03-16
US9714234B2 (en) 2017-07-25
MX2015016771A (es) 2016-03-31
WO2014210087A1 (en) 2014-12-31
EP3013815A1 (en) 2016-05-04
IL243295A0 (en) 2016-02-29
SG11201510028PA (en) 2016-01-28
BR112015031432A2 (pt) 2017-07-25
KR20160022890A (ko) 2016-03-02
JP2016523908A (ja) 2016-08-12
EP3013815B1 (en) 2017-05-03
CA2916504A1 (en) 2014-12-31
US20160200710A1 (en) 2016-07-14
CN105473573A (zh) 2016-04-06
AU2014302550A1 (en) 2016-02-11
JP6353530B2 (ja) 2018-07-04

Similar Documents

Publication Publication Date Title
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
KR102346508B1 (ko) 키나제 억제제로서 유용한 치환된 테트라히드로카르바졸 및 카르바졸 카르복스아미드 화합물
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
AU2015335703B2 (en) Carbazole derivatives
AU2015335783B2 (en) Tricyclic atropisomer compounds
HK1223359B (en) Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241228

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241228

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241228